APLS

Apellis Pharmaceuticals Inc.

This asset is no longer available for investment.

View all assets

Price

return (12m)

p/e

0.00

p/bv

0.00

DIVIDEND YIELD

0.00%

APLS price

Apellis Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment APLS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals APLS

Valuation

P/E

0.00

Sector -3.50

Industry -3.50

P/BV

0.00

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector 2.01

Industry 2.01

EV/EBITDA

-1.68

Sector -214.99

Industry -214.99

EV/EBIT

-1.70

Sector -47.59

Industry -47.59

P/EBITDA

Sector -21.41

Industry -21.41

P/EBIT

Sector -28.65

Industry -28.65

P/Total Assets

Sector 1.19

Industry 1.19

P/Net Current Assets

Sector -11.97

Industry -11.97

P/Working Capital

Sector -167.95

Industry -167.95

EPS

0.88

Sector -1.81

Industry -1.81

BVPS

3.29

Sector 2.06

Industry 2.06

Efficiency

Gross Margin

90.12%

Sector 41.30%

Industry 41.30%

EBITDA Margin

9.86%

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

9.76%

Sector -4,185,659.35%

Industry -4,185,659.35%

Operating Margin

14.95%

Sector -35.21%

Industry -35.21%

Net Profit Margins

10.03%

Sector -35.91%

Industry -35.91%

Asset Turnover

0.25

Sector 0.02

Industry 0.02

Profitability

ROE

26.72%

Sector -56.04%

Industry -56.04%

ROA

10.24%

Sector -60.31%

Industry -60.31%

ROIC

Sector -2,335.95%

Industry -2,335.95%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

Sector 2.89

Industry 2.89

Net Debt / EBITDA

-1.68

Sector -14,066,680.10

Industry -14,066,680.10

Net Debt / EBIT

-1.70

Sector -8.06

Industry -8.06

Net Debt / Equity

-0.11

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

0.87

Sector -0.85

Industry -0.85

Equity/Assets

0.38

Sector 0.46

Industry 0.46

Liabilities/Assets

0.62

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

75.41%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals APLS

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Apellis Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$0.00

Fair Value

$8.07

Upside

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
APLS Apellis Pharmaceuticals Inc.	$0.00	-100.00%	0.00%	0.00	0.00	26.72%	10.03%
JNJ Johnson & Johnson	$269.33	55.44%	1.96%	30.82	7.63	24.76%	21.48%
PFE Pfizer Inc.	$27.49	22.33%	6.26%	35.85	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$263.93	23.34%	2.59%	73.99	-78.76	-106.44%	9.81%
NVO Novo Nordisk A/S	$43.19	-26.70%	4.29%	10.56	5.61	53.11%	35.32%
MRK Merck & Co. Inc.	$146.11	87.14%	2.31%	113.21	8.55	7.55%	4.76%
AZN AstraZeneca PLC	$166.35	9.78%	1.94%	19.88	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$62.71	43.77%	4.04%	13.67	5.68	41.55%	18.85%
ZTS Zoetis Inc.	$72.66	-49.60%	2.88%	11.47	9.64	84.02%	27.77%
AMGN Amgen Inc.	$383.04	43.28%	2.60%	23.66	17.70	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$784.44	31.54%	0.47%	18.63	2.54	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$111.35	46.87%	0.00%	31.57	90.97	288.13%	24.86%
MCK McKesson Corporation	$874.67	27.00%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$506.08	30.72%	0.00%	29.15	6.34	21.76%	35.00%
CAH Cardinal Health Inc.	$224.45	52.89%	0.91%	30.53	-19.32	-63.29%	0.68%
ARGX argenx SE	$994.44	35.42%	0.00%	2.24	2.63	117.11%	44.68%
HRMY Harmony Biosciences Holdings Inc.	$42.23	31.71%	0.00%	13.50	2.45	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

APLS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (1 people)

United States

17 years

Founded: 2009

2017

Time since IPO - 9 years

374

Employees

Apellis Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $-, with shareholders equity totaling $414.92 million.

The company employs approximately 374 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Apellis Pharmaceuticals Inc. reported $1.11 billion in revenue, generating net income of $110.88 million.

Key financial metrics include a P/E ratio of 0.00, a price-to-book (P/B) ratio of 0.00, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker APLS.

Market cap

Net worth

$414.92 million

$414,923,000.00

Assets

$1.08 billion

$1,082,532,000.00

Total Shares Outstanding

126.02 million

126,024,000

Average Daily Trading Volume

$4.47 million

$4,469,455.00

Sector

Health Care

Industry

Biotechnology

APLS

APLS revenue and profits

Financial Results APLS

DRAG THE FRAME TO SEE MORE DATA

APLS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$874.67 25,76% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$224.45 51,61% (12M)

P/E

30.53

0.91%

ROE

-63.29%

P/BV

-19.32

JNJ - Johnson & Johnson

$269.33 56,33% (12M)

P/E

30.82

1.96%

ROE

24.76%

P/BV

7.63

ABBV - AbbVie

$263.93 22,42% (12M)

P/E

73.99

2.59%

ROE

-106.44%

P/BV

-78.76

MRK - Merck & Co.

$146.11 85,19% (12M)

P/E

113.21

2.31%

ROE

7.55%

P/BV

8.55

AZN - AstraZeneca

$166.35 9,17% (12M)

P/E

19.88

1.94%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$27.49 22,43% (12M)

P/E

35.85

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$874.67 25,76% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$224.45 51,61% (12 M)

P/L

30.53

0.91%

ROE

-63.29%

P/VP

-19.32

JNJ - Johnson & Johnson

$269.33 56,33% (12 M)

P/L

30.82

1.96%

ROE

24.76%

P/VP

7.63

ABBV - AbbVie

$263.93 22,42% (12 M)

P/L

73.99

2.59%

ROE

-106.44%

P/VP

-78.76

MRK - Merck & Co.

$146.11 85,19% (12 M)

P/L

113.21

2.31%

ROE

7.55%

P/VP

8.55

AZN - AstraZeneca

$166.35 9,17% (12 M)

P/L

19.88

1.94%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$27.49 22,43% (12 M)

P/L

35.85

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Apellis Pharmaceuticals (APLS) today?

A cotação de Apellis Pharmaceuticals (APLS) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Apellis Pharmaceuticals (APLS) iniciou o ano negociando na casa dos US$ 25.86 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Apellis Pharmaceuticals (APLS) e dados de ações do Ibovespa e mercados internacionais.

Quando Apellis Pharmaceuticals (APLS) paga dividendos?

Apellis Pharmaceuticals (APLS) não distribuiu dividendos no último ano.

Is Apellis Pharmaceuticals (APLS) a good investment?

Atualmente, Apellis Pharmaceuticals (APLS) está cotada a US$ 0.00, com um P/L de 0.00, representando um desvio de -812% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Apellis Pharmaceuticals (APLS) stock?

Investir em ações de Apellis Pharmaceuticals (APLS) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Apellis Pharmaceuticals (APLS) yield today?

A rentabilidade de Apellis Pharmaceuticals (APLS) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Apellis Pharmaceuticals (APLS) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

APLS

Apellis Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment APLS

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING APLS WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc.

United States

17 years

2017

374

PROFIT X PRICE APLS

Financial Results APLS

APLS cash flow

Asset, Revenue and Profit Growth - APLS

APLS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions